Bell Investment Advisors’s Axsome Therapeutics AXSM Stock Holding History

Bell Investment Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.43K	Hold	14	–	–	﹤0.01%	1130
2026 Q1	$2.37K	Hold	14	–	–	﹤0.01%	1278
2025 Q4	$2.56K	Buy	14 +3	+27%	+$419	﹤0.01%	1261
2025 Q3	$1.34K	Sell	11 -5	-31%	-$563	﹤0.01%	1472
2025 Q2	$1.67K	Hold	16	–	–	﹤0.01%	1419
2025 Q1	$1.87K	Hold	16	–	–	﹤0.01%	1328
2024 Q4	$1.35K	Hold	16	–	–	﹤0.01%	1486
2024 Q3	$1.44K	Hold	16	–	–	﹤0.01%	1469
2024 Q2	$1.29K	Hold	16	–	–	﹤0.01%	1528
2024 Q1	$1.28K	Hold	16	–	–	﹤0.01%	1526
2023 Q4	$1.27K	Buy	+16	New	+$1.07K	﹤0.01%	1509
2023 Q3	–	Sell	-13	Closed	-$935	–	1933
2023 Q2	$935	Buy	+13	New	+$959	﹤0.01%	1615
2021 Q4	–	Sell	-10	Closed	–	–	1772
2021 Q3	$0	Buy	+10	New	+$390	﹤0.01%	1720

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bell Investment Advisors's AXSM Position: Q2 2026 in Review

Bell Investment Advisors held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 14 shares worth $3.43K. The position accounts for ﹤0.01% of the portfolio, ranked #1130.

Bell Investment Advisors first reported a position in AXSM in Q3 2021 and has held it in 13 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Bell Investment Advisors held 14 shares of Axsome Therapeutics worth $3.43K as of Q2 2026.
Bell Investment Advisors left its Axsome Therapeutics share count unchanged in Q2 2026.
Axsome Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1130 holding.
Bell Investment Advisors first reported a position in Axsome Therapeutics in Q3 2021 and has held it in 13 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.